Key result
Higher trough rivaroxaban levels are linked to greater early thrombus regression in acute PE.
Why the study?
The association between trough rivaroxaban plasma concentrations and early thrombus regression in patients with acute PE needed to be evaluated.
Does higher trough rivaroxaban plasma concentration improve early thrombus regression in patients with acute pulmonary embolism?
Cohort (n=51)
Yes
Does higher trough rivaroxaban plasma concentration improve early thrombus regression in patients with acute pulmonary embolism?
Higher trough rivaroxaban plasma concentrations are positively associated with greater early thrombus regression on CT in patients with acute pulmonary embolism, and prothrombin time strongly correlates with rivaroxaban exposure.
Answers are grounded in this paper and cite their sources.
Should not yet change rivaroxaban dosing in acute PE; hypothesis-generating for concentration-guided trials.
Objectives To evaluate the association between trough rivaroxaban plasma concentrations and early thrombus regression in patients with acute pulmonary embolism (PE).Methods This study was a sub-analysis of the multicenter, prospective SAKURA PE/DVT REGISTRY. The thrombus regression rate was calculated using contrast-enhanced computed tomography performed at diagnosis and approximately two weeks after treatment initiation. Trough rivaroxaban plasma concentrations were measured using a chromogenic anti-factor Xa assay. Correlations between plasma concentrations, thrombus regression rates, and coagulation parameters were analyzed.Patients Among 153 patients with acute PE treated with direct oral anticoagulants, 106 received rivaroxaban, and trough plasma concentrations were measured in 51 patients.Results The median trough rivaroxaban plasma concentration was 120.0 (55.6-186.0) ng/mL, with substantial interindividual variability. Trough rivaroxaban plasma concentrations were positively correlated with the thrombus regression rate in all patients (ρ = 0.33, P = 0.018) and in the intensive therapy group (ρ = 0.41, P = 0.009). In the multivariable analysis, log-transformed rivaroxaban plasma concentrations were independently associated with the thrombus regression rate in the intensive therapy group (β = 9.79, 95% confidence interval 0.72-18.86; P = 0.035). Prothrombin time was strongly correlated with rivaroxaban plasma concentration (ρ = 0.85, P < 0.001). Plasma concentrations tended to increase with age and showed greater variability in elderly patients.Conclusion Higher trough rivaroxaban plasma concentrations were associated with greater early thrombus regression in patients with acute PE. Prothrombin time may be a practical surrogate for rivaroxaban exposure and may support individualized anticoagulation strategies in selected patients.
No takes yet. Share an insight, caveat, or question.
Migita et al. (2026) conducted a cohort in Acute pulmonary embolism (PE) (n=51). Trough rivaroxaban plasma concentration vs. Intensive therapy (15 mg twice daily) vs. under-dose therapy (20, 15, or 10 mg/day) was evaluated on Association between trough rivaroxaban plasma concentrations and thrombus regression rate on 2-week follow-up CT (ρ = 0.33 (all patients); β = 9.79 (multivariable, intensive therapy group), 95% CI 0.72-18.86, p=0.018). Trough rivaroxaban plasma concentrations positively correlated with early 2-week thrombus regression rates in acute pulmonary embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: